ORMP
Oramed Pharmaceuticals Inc.
Biotechnology
Market Cap$160M
5Y Perf.+24.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ORMP vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
ORMP vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ORMP | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $160M | $85M |
| Revenue (TTM) | $2M | $242K |
| Net Income (TTM) | $-24M | $-38M |
| Gross Margin | -2.4% | 59.5% |
| Operating Margin | -6.8% | -63.0% |
| Total Debt | $372K | $631K |
| Cash & Equiv. | $54M | $8M |
ORMP vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ORMP
NRXP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Oramed Pharmaceutic… (ORMP) | 100 | 124.5 | +24.5% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORMP vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ORMP leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
ORMP
Oramed Pharmaceuticals Inc.
The Income Pick
ORMP carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.21
- -55.2% 10Y total return vs NRXP's -96.8%
- Lower volatility, beta 1.21, Low D/E 0.3%, current ratio 25.19x
Best for: income & stability and long-term compounding
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP is the clearest fit if your priority is growth exposure.
- EPS growth 43.9%
- 101.1% revenue growth vs ORMP's -100.0%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs ORMP's -100.0% |
| Quality / Margins | ORMP | -12.1% margin vs NRXP's -157.3% |
| Stability / Safety | ORMP | Beta 1.21 vs NRXP's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ORMP | +87.4% vs NRXP's +55.3% |
| Efficiency (ROA) | ORMP | -14.9% ROA vs NRXP's -489.9% |
ORMP vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ORMP vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLORMPLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
0leads
ORMPOramed Pharmaceutical…
5leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ORMP4/5
Valuation MetricsMultiples, price ratios, and targets
ORMP1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ORMP4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ORMP6/6
Risk & VolatilityBeta, volatility, and downside exposure
ORMP2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ORMP leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ORMP is the larger business by revenue, generating $2M annually — 8.3x NRXP's $242,000. ORMP is the more profitable business, keeping -12.1% of every revenue dollar as net income compared to NRXP's -157.3%.
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $242,000 |
| EBITDAEarnings before interest/tax | -$14M | -$31M |
| Net IncomeAfter-tax profit | -$24M | -$38M |
| Free Cash FlowCash after capex | -$16M | -$12M |
| Gross MarginGross profit ÷ Revenue | -2.4% | +59.5% |
| Operating MarginEBIT ÷ Revenue | -6.8% | -63.0% |
| Net MarginNet income ÷ Revenue | -12.1% | -157.3% |
| FCF MarginFCF ÷ Revenue | -8.0% | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +40.9% | -80.0% |
ORMP leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
ORMP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $160M | $85M |
| Enterprise ValueMkt cap + debt − cash | $106M | $78M |
| Trailing P/EPrice ÷ TTM EPS | -8.32x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 69.15x |
| Price / BookPrice ÷ Book value/share | 1.10x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ORMP leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ORMP leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs ORMP's 3/9, reflecting solid financial health.
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -15.7% | — |
| ROA (TTM)Return on assets | -14.9% | -4.9% |
| ROICReturn on invested capital | -6.5% | — |
| ROCEReturn on capital employed | -8.1% | — |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$54M | -$7M |
| Cash & Equiv.Liquid assets | $54M | $8M |
| Total DebtShort + long-term debt | $372,000 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | -1.66x | -24.18x |
ORMP leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ORMP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ORMP five years ago would be worth $3,803 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, ORMP leads with a +87.4% total return vs NRXP's +55.3%. The 3-year compound annual growth rate (CAGR) favors ORMP at 11.1% vs NRXP's -21.0% — a key indicator of consistent wealth creation.
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +43.0% | +16.8% |
| 1-Year ReturnPast 12 months | +87.4% | +55.3% |
| 3-Year ReturnCumulative with dividends | +37.3% | -50.6% |
| 5-Year ReturnCumulative with dividends | -62.0% | -99.1% |
| 10-Year ReturnCumulative with dividends | -55.2% | -96.8% |
| CAGR (3Y)Annualised 3-year return | +11.1% | -21.0% |
ORMP leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
ORMP leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ORMP is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than NRXP's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ORMP currently trades 92.7% from its 52-week high vs NRXP's 79.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.91x |
| 52-Week HighHighest price in past year | $4.22 | $3.84 |
| 52-Week LowLowest price in past year | $1.98 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +92.7% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 56.9 | 64.7 |
| Avg Volume (50D)Average daily shares traded | 126K | 913K |
ORMP leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ORMPOramed Pharmaceut… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 8 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ORMP leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallOramed Pharmaceuticals Inc. (ORMP)Leads 5 of 6 categories
Loading custom metrics...
ORMP vs NRXP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ORMP or NRXP a better buy right now?
Analysts rate Oramed Pharmaceuticals Inc.
(ORMP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORMP or NRXP?
Over the past 5 years, Oramed Pharmaceuticals Inc.
(ORMP) delivered a total return of -62. 0%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: ORMP returned -55. 2% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORMP or NRXP?
By beta (market sensitivity over 5 years), Oramed Pharmaceuticals Inc.
(ORMP) is the lower-risk stock at 1. 21β versus NRx Pharmaceuticals, Inc. 's 1. 91β — meaning NRXP is approximately 57% more volatile than ORMP relative to the S&P 500.
04Which is growing faster — ORMP or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to -435. 7% for Oramed Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORMP or NRXP?
Oramed Pharmaceuticals Inc.
(ORMP) is the more profitable company, earning -1208. 1% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps -1208. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORMP leads at -683. 6% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ORMP or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ORMP or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Oramed Pharmaceuticals Inc.
(ORMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ORMP: -55. 2%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ORMP and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.